Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa

Article Infectious Diseases

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022)

Helio S. Sader et al.

Summary: A total of 35,360 Enterobacterales isolates were collected from US medical centers from 2018 to 2022. Among them, 7.4% were identified as multidrug-resistant (MDR). Susceptibility testing and whole genome sequencing were conducted to determine the resistance profiles and carbapenemase genes. The most active β-lactamase inhibitor combination against carbapenem-resistant Enterobacterales (CRE) isolates was ceftazidime-avibactam, followed by meropenem-vaborbactam and imipenem-relebactam. Ceftazidime-avibactam exhibited greater activity against OXA-48-type producers.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2023)

添加到收藏夹

Article Infectious Diseases

Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study

Jinnethe Reyes et al.

Summary: This study investigated the characteristics and outcomes of carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections and the distribution and clinical significance of carbapenemases. The results showed that carbapenemase-producing CRPA infections were associated with increased 30-day mortality, and the prevalence of carbapenemase genes varied by region. These findings highlight the therapeutic challenges posed by these carbapenem-resistant organisms.

LANCET MICROBE (2023)

添加到收藏夹

Article Immunology

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

Pranita D. Tamma et al.

Summary: This article provides updated guidance on the treatment of infections caused by ESBL-E, CRE, and DTR-P. aeruginosa. The guidance was developed by a panel of infectious diseases specialists and includes preferred and alternative treatment recommendations. The document emphasizes the importance of consulting with an infectious diseases specialist for the treatment of antimicrobial-resistant infections.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Infectious Diseases

Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial

Gabriel Torrens et al.

Summary: This study investigated the susceptibility profiles and resistome of Pseudomonas aeruginosa isolates from European ICUs. The results revealed a high prevalence of resistance, except for colistin, with a wide intercountry variability determined by the dissemination of XDR high-risk clones.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

添加到收藏夹

Article Infectious Diseases

The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa

Christian M. Gill et al.

Summary: Ceftolozane/tazobactam and ceftazidime/avibactam have demonstrated high activity against carbapenem-resistant Pseudomonas aeruginosa, especially in the absence of carbapenemases. Ceftazidime/avibactam showed higher susceptibility in the global CR-PA collection compared to ceftolozane/tazobactam. The 33% carbapenemase positivity rate, with VIM and GES being the most common carbapenemases, highlights the need for effective therapeutic options in clinically challenging CR-PA infections.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Microbiology